E.g., 05/26/2017
E.g., 05/26/2017

bioMérieux supporting the launch of the AMR Industry Alliance

22 May, 2017

Marcy l'Etoile, France, May 2017 - Media Statement - bioMérieux, a world leader in the field of in vitro diagnostics, is pleased to support the launch of the AMR Industry Alliance, a new alliance to drive and measure industry progress to curb antimicrobial resistance.

With New Instrument and Assay Claims, BioMérieux Takes on Antibiotic Stewardship

11 May, 2017

With a recently approved blood culture system, new indications for its procalcitonin (PCT) diagnostic assay, and an arsenal of molecular testing tools, bioMérieux is aiming to become a leader in the increasingly competitive field of antibiotic stewardship.

Sepsis Alliance and bioMérieux, Inc. Expand Partnership for 2017 to Promote Sepsis Awareness and Prevention

10 May, 2017

Durham, NC – San Diego, CA (May 10, 2017) – bioMérieux, a world leader in the field of in vitro diagnostics, is proud to announce that its U.S. affiliate, bioMérieux Inc. will be expanding its partnership with Sepsis Alliance. bioMérieux Inc. will serve as the 2017 National Sepsis Awareness and Education Title Sponsor, including sponsorship of Sepsis Alliance’s Sepsis Challenge™ events.

bioMérieux 2016 Annual Report

10 May, 2017

A world leader in the field of in vitro diagnostics for over 50 years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors. In 2016, revenues reached €2,103 million, with more than 90% of international sales.

The war against superbugs starts here in North Carolina

08 May, 2017

Nearly every day, there are new reports of antibiotic resistance bacteria – superbugs – that are becoming more difficult to treat. Early this year, the Centers for Disease Control and Prevention reported on the death of a woman in Nevada who had a resistant bacterial infection that was impervious to 26 different antibiotic drugs.

bioMérieux – First-Quarter 2017 Business Review

20 April, 2017

Marcy l'Étoile (France), April 20, 2017 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the three months ended March 31, 2017.

bioMérieux receives FDA 510(k) clearance for its BacT/ALERT® VIRTUO™ fully automated blood culture system

06 April, 2017

Marcy l’Étoile (France) - April 6, 2017 – bioMérieux, a major player in the field of in vitro diagnostics, and the world leader in microbiology, announces that BacT/ALERT® VIRTUO™, its fully automated blood culture system, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

Spring Holiday Shipping Schedule 2017

03 April, 2017

Please be advised that bioMérieux Inc. sites in Durham, St. Louis, Louisville and Lombard will be closed on Friday, April 14 in observance of the upcoming holiday. 

bioMérieux Opens New Production Line at Durham Facility, Expanding Capacity of BacT/ALERT® Blood Culturing Bottles Vital in Fight Against Resistant Infections 

31 March, 2017

Durham, NC – March 29, 2017 – bioMérieux, a world leader in the field of in vitro diagnostics, is proud to announce the opening of a new production line at its Americas Headquarters in Durham, North Carolina.

bioMérieux’s VIDAS® B•R•A•H•M•S PCT™ becomes the first FDA-cleared procalcitonin assay as an aid for antibiotic stewardship in respiratory infections and sepsis

24 February, 2017

bioMérieux, a world leader in the field of in vitro diagnostics, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the expanded use of VIDAS® B•R•A•H•M•S PCT™, an automated assay measuring procalcitonin (PCT) levels, to help clinicians make important decisions regarding the optimal use of antibiotics in two common clinical situations: lower respiratory tract infections (LRTI) and sepsis.

Pioneering diagnostics